Want to see GALT full AI Analyst Report?
GALT Stock Chart & Stats
$4.15
-$0.09(-2.59%)
At close: 4:00 PM EDT
$4.15
-$0.09(-2.59%)
Day’s Range― - ―
52-Week Range$2.03 - $7.13
Previous Close$3.42
Volume305.15K
Average Volume (3M)345.45K
Market Cap
$420.54M
Enterprise Value$432.36
Total Cash (Recent Filing)$13.27M
Total Debt (Recent Filing)$137.70M
Price to Earnings (P/E)―
Beta0.42
Next Earnings
Nov 16, 2026EPS Estimate
-0.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding100,849,650
10 Day Avg. Volume271,919
30 Day Avg. Volume345,455
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)-2.11
Price to Sales (P/S)0.00
P/FCF Ratio-11.13
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$11.00Price Target Upside165.06% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.37
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Major Debt Reduction Strengthens Financial FlexibilityRemoving approximately $105.8 million of debt materially reduces liabilities and near-term repayment pressure. The transaction improves financial flexibility for clinical development, although the resulting equity issuance is dilutive and does not eliminate the need for funding.
FDA Alignment Supports A Defined Phase 3 PathwayAgreement with the FDA on the endpoint, design and regulatory route reduces development uncertainty for belapectin. A defined confirmatory framework may improve partnering prospects and supports a credible path toward potential approval in MASH cirrhosis.
Losses And Cash Burn Have Improved From Prior PeriodsThe reduction in operating cash burn and losses suggests some improvement in cost control and resource efficiency. This is a constructive operating trend for a development-stage biotech, though cash generation remains negative and external financing is still required.
Bears Say
No Recurring Revenue And Persistent Operating LossesThe absence of product revenue leaves the company dependent on financing, partnerships or eventual clinical success to fund operations. Persistent operating and net losses also limit internal reinvestment capacity and increase execution risk over the next several quarters.
Ongoing Negative Cash Flow Creates Funding DependenceContinued cash burn means clinical programs cannot currently be funded from operations. The company must rely on additional capital, strategic partnerships or other financing, exposing shareholders to potential dilution and creating execution risk if funding conditions weaken.
Balance Sheet Remains Highly Leveraged With Negative EquityDespite the recent debt conversion, reported metrics still show deeply negative equity, substantial debt and a thin asset base. This weak capital structure limits financial resilience and leaves material refinancing, dilution and solvency risks while development spending continues.
Galectin Therapeutics News
GALT FAQ
What was Galectin Therapeutics Inc’s price range in the past 12 months?
Galectin Therapeutics Inc lowest stock price was $2.02 and its highest was $7.13 in the past 12 months.
What is Galectin Therapeutics Inc’s market cap?
Galectin Therapeutics Inc’s market cap is $420.54M.
When is Galectin Therapeutics Inc’s upcoming earnings report date?
Galectin Therapeutics Inc’s upcoming earnings report date is Nov 16, 2026 which is in 73 days.
How were Galectin Therapeutics Inc’s earnings last quarter?
Galectin Therapeutics Inc released its earnings results on Aug 14, 2026. The company reported -$0.14 earnings per share for the quarter, missing the consensus estimate of -$0.09 by -$0.05.
Is Galectin Therapeutics Inc overvalued?
According to Wall Street analysts Galectin Therapeutics Inc’s price is currently Undervalued.
Does Galectin Therapeutics Inc pay dividends?
Galectin Therapeutics Inc does not currently pay dividends.
What is Galectin Therapeutics Inc’s EPS estimate?
Galectin Therapeutics Inc’s EPS estimate is -0.05.
How many shares outstanding does Galectin Therapeutics Inc have?
Galectin Therapeutics Inc has 100,849,650 shares outstanding.
What happened to Galectin Therapeutics Inc’s price movement after its last earnings report?
Galectin Therapeutics Inc reported an EPS of -$0.14 in its last earnings report, missing expectations of -$0.09. Following the earnings report the stock price went down -2.55%.
Which hedge fund is a major shareholder of Galectin Therapeutics Inc?
Currently, no hedge funds are holding shares in GALT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Galectin Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.00 (165.06% Upside)
$11.00 (165.06% Upside)
Blogger Sentiment
Bullish
GALT Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 2.2%
Last 30 Days ▼ 2.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
1.35%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-4.97%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Galectin Therapeutics Inc
Galectin Therapeutics Inc. is a biopharmaceutical company in the clinical development phase, dedicated to discovering and advancing new therapies for a spectrum of illnesses, including fibrotic disorders and various cancers. The company's flagship therapeutic agent is belapectin (GR-MD-02), an inhibitor of galectin-3, which is a complex polysaccharide polymer. This compound is currently undergoing Phase III clinical trials, assessing its effectiveness in treating liver scarring linked to fatty liver disease and non-alcoholic steatohepatitis (NASH) cirrhosis, alongside its potential for cancer treatment. Beyond belapectin, Galectin Therapeutics is progressing GM-CT-01 through preclinical stages for the management of cardiac and vascular fibrosis. The company is also actively exploring additional uses for belapectin in conditions like psoriasis, lung fibrosis, and kidney fibrosis. Furthermore, through Galectin Sciences, LLC – a joint venture established with SBH Sciences, Inc. – the firm is involved in researching and developing small organic molecules designed to block galectin-3, intended for oral administration. Established in 2000, the company was initially known as Pro-Pharmaceuticals, Inc. before officially changing its name to Galectin Therapeutics, Inc. in May 2011. Its corporate headquarters are located in Norcross, Georgia.
GALT Stock 12 Month Forecast
Average Price Target
$11.00
▲(165.06% Upside)
Technical Analysis
Omeros
―
Voyager Therapeutics
―
Tectonic Therapeutic
―
Jade Biosciences
―
Tenaya Therapeutics
―
Ownership Overview
51.09% Insiders
2.55% Mutual Funds
2.32% Other Institutional Investors
39.76% Public Companies and
Individual Investors